✦ LIBER ✦

Cost-Effectiveness Analyses of Natalizumab for 2nd Line Versus Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients in Brazil

✍ Scribed by Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and cost-effectiveness

✍ Boster, A.; Bartoszek, M. P.; O'Connell, C.; Pitt, D.; Racke, M. 📂 Article 📅 2011 🏛 SAGE Publications 🌐 English ⚖ 160 KB

Cost-Effectiveness Analyses of Natalizum

✍ Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PND6 COST-EFFECTIVENESS OF GLATIRAMER AC

✍ JB Graham; SR Earnshaw; J Castelli-Haley; M Oleen-Burkey; KP Johnson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PND28 Cost-Effectiveness Analysis of Int

✍ R. Sánchez-de la Rosa; E. Sabater; M.A. Casado 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost analysis of glatiramer acetate vs.

✍ Rainel Sanchez-de la Rosa, Eliazar Sabater, Miguel A Casado 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 206 KB